CEL-SCI (CVM)

Executive Summary

CEL-SCI Corporation is a clinical-stage biotechnology company focused on immunotherapy for cancer, with its lead candidate Multikine (Leukocyte Interleukin, Injection) in Phase 3 development for head and neck squamous cell carcinoma (HNSCC). Multikine is an off-the-shelf neoadjuvant cytokine therapy designed to boost the immune system prior to standard treatment. The company completed a pivotal Phase 3 trial (NCT01265849) in locally advanced primary HNSCC, which missed its primary endpoint in the overall population but showed a significant survival benefit in a subset of patients with lower tumor burden and no lymph node involvement. CEL-SCI is seeking FDA approval based on this subset analysis, which has been a point of contention with regulators. The company's stock has been volatile due to regulatory uncertainty. CEL-SCI's pipeline also includes earlier-stage programs in condyloma and perianal warts, but Multikine remains the primary value driver. With a market cap under $15M, the stock offers a high-risk, high-reward opportunity if the FDA accepts the subset data.

Upcoming Catalysts (preview)

• H2 2026FDA Regulatory Submission for Multikine in HNSCC Subpopulation20% success
• Q3 2026Publication of Phase 3 Subset Analysis Data in Peer-Reviewed Journal70% success
• H1 2027Strategic Partnership or Licensing Deal for Multikine30% success